Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Rocket Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 9IP1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 9IP1 exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 9IP1 exceeded the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Rocket Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Rocket Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 9IP1 (€21.8) is trading below our estimate of fair value (€115.87)
Significantly Below Fair Value: 9IP1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 9IP1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 9IP1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 9IP1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 9IP1 is overvalued based on its PB Ratio (5.2x) compared to the DE Biotechs industry average (3.5x).
How is Rocket Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9IP1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9IP1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9IP1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 9IP1's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 9IP1's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 9IP1's Return on Equity is forecast to be high in 3 years time
How has Rocket Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 9IP1 is currently unprofitable.
Growing Profit Margin: 9IP1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 9IP1 is unprofitable, and losses have increased over the past 5 years at a rate of -65.9% per year.
Accelerating Growth: Unable to compare 9IP1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9IP1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 9IP1 has a negative Return on Equity (-36.54%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Rocket Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 9IP1's short term assets ($245.6M) exceed its short term liabilities ($22.2M).
Long Term Liabilities: 9IP1's short term assets ($245.6M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: 9IP1's debt to equity ratio (19%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 9IP1's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 9IP1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 9IP1's debt is covered by short term assets (assets are 5.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9IP1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9IP1 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of -72.3% each year.
What is Rocket Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 9IP1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 9IP1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9IP1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9IP1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 9IP1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gaurav Shah (44yo)
Mr. Gaurav Shah, M.D. serves as the Chief Executive Officer, President and Director of Rocket Pharmaceuticals, Ltd since January 2018.
CEO Compensation Analysis
Compensation vs Market: Gaurav's total compensation ($USD6.38M) is above average for companies of similar size in the German market ($USD1.49M).
Compensation vs Earnings: Insufficient data to compare Gaurav's compensation with company performance.
|CEO, President & Director||2.1yrs||US$6.38m||1.27% $15.2m|
|COO & Executive VP of Development||2.1yrs||US$2.99m||0.22% $2.6m|
|Chief Medical Officer & Senior VP of Clinical Development||2.1yrs||US$1.36m||no data|
|Senior VP of Finance & Principal Financial Officer||0.3yrs||no data||no data|
|Senior Controller||2.1yrs||no data||no data|
|Senior Vice President of Corporate Development & Strategy and IRO||0yrs||no data||no data|
|Senior Vice President of Business Development & Operations||0yrs||no data||no data|
Experienced Management: 9IP1's management team is considered experienced (2.1 years average tenure).
|CEO, President & Director||2.1yrs||US$6.38m||1.27% $15.2m|
|Independent Director||2.1yrs||US$608.85k||no data|
|Independent Director||4.1yrs||US$731.01k||no data|
|Independent Director||2.1yrs||US$600.44k||0.21% $2.5m|
|Independent Director||2.1yrs||US$598.59k||no data|
Experienced Board: 9IP1's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.2%.
Rocket Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Rocket Pharmaceuticals, Inc.
- Ticker: 9IP1
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.301b
- Listing Market Cap: US$1.201b
- Shares outstanding: 54.17m
- Website: https://www.rocketpharma.com
Number of Employees
- Rocket Pharmaceuticals, Inc.
- The Empire State Building
- Suite 7530
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RCKT||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 2018|
|9IP1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2018|
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:45|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.